Effect of BRAF(V600E )mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model by Cahill, Susanne et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Molecular Cancer
Open Access Research
Effect of BRAFV600E mutation on transcription and 
post-transcriptional regulation in a papillary thyroid carcinoma 
model
Susanne Cahill1, Paul Smyth1, Karen Denning1, Richard Flavin1, 
Jinghuan Li1, Astrid Potratz2, Simone M Guenther2, Richard Henfrey2, 
John J O'Leary1 and Orla Sheils*1
Address: 1Dept. of Histopathology, University of Dublin, Trinity College, Dublin, Ireland and 2Applied Biosystems, Foster City, CA, USA
Email: Susanne Cahill - sucahill@tcd.ie; Paul Smyth - smythpa@tcd.ie; Karen Denning - Denningk@tcd.ie; Richard Flavin - flavinr@tcd.ie; 
Jinghuan Li - jinghual@tcd.ie; Astrid Potratz - astrid.ferlinz@eur.appliedbiosystems.com; 
Simone M Guenther - simone.m.guenther@eur.appliedbiosystems.com; Richard Henfrey - richard.henfrey@appliedbiosystems.com; 
John J O'Leary - olearyjj@tcd.ie; Orla Sheils* - osheils@tcd.ie
* Corresponding author    
Abstract
Background: microRNAs (miRNAs) are a group of non-coding single stranded RNAs measuring
approximately 22 nucleotides in length that have been found to control cell growth, differentiation
and apoptosis. They negatively regulate target genes and have recently been implicated in
tumourigenesis. Furthermore, miRNA expression profiling correlates with various cancers, with
these genes thought to act as both tumour suppressors and oncogenes. Recently, a point mutation
in the BRAF gene leading to a V600E substitution has been identified as the most common genetic
change in papillary thyroid carcinoma (PTC) occurring in 29–69% of cases. This mutation leads to
aberrant MAPK activation that is implicated in tumourigenesis.
Aim:  The aim of this study was to identify the effect that BRAF oncogene has on post-
transcriptional regulation in PTC by using microRNA analysis.
Results: A unique miRNA expression signature differentiated between PTC cell lines with BRAF
mutations and a normal thyroid cell line. 15 miRNAs were found to be upregulated and 23 miRNAs
were downregulated. Several of these up/down regulated miRNAs may be involved in PTC
pathogenesis. miRNA profiling will assist in the elucidation of disease pathogenesis and
identification biomarkers and targets.
Background
Papillary thyroid carcinoma (PTC) is the most commonly
occurring thyroid malignancy accounting for approxi-
mately 80% of cases. Genetically PTC is defined by several
alterations which cause abnormal activation of the
mitogen-activated protein kinase (MAPK) pathway, the
most prevalent being point mutations in the intracellular
signalling kinase BRAF [1,2]. An activating mutation in
BRAF (V600E) leads to constitutive activation and hence
de-regulation of MAPK pathway. Several groups have
reported that PTCs harbouring mutations in BRAF have
more aggressive properties, present more often with extra-
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thyroidal invasion and also at a more advanced stage. His-
tological features such as the classic PTC architecture and
tall cell features are also associated with the BRAF onco-
gene [3,4].
Despite this range of knowledge thyroid carcinoma still
poses a significant diagnostic challenge and understand-
ing of the complete range of genes and pathways involved
in its pathogenesis is incomplete. Until recently biomar-
ker discovery has concentrated largely on protein coding
RNAs in a quest to identify cancer associated genes
involved in thyroid carcinogenesis [5-7]. The recent dis-
covery however that a large group of non-coding RNAs
called microRNAs (miRNAs) may potentially play a role
in cancer has led to a proliferation of miRNA related
research of late including the publication of several key
reviews [8-12]. These small non-coding RNAs constitute a
novel class of gene regulators that function by negatively
regulating gene expression by targeting mRNAs for cleav-
age or translational repression. Several recent studies on
the regulatory functions of miRNAs suggest that they play
critical roles in central processes such as development, cell
proliferation and differentiation, stress resistance, metab-
olism and apoptosis all of which are involved in tumour-
igenesis [13,15]. Not surprisingly aberrant miRNA
expression has been implicated in cancer development
and a hypothesis has emerged suggesting that tumours
may each have a discrete "miRNA signature" [16-20]. Dif-
ferential expression of miRNAs between malignant tissue
and normal tissue and between different types of tumour,
has been shown in several key studies, indicating that
miRNAs are determinants of clinical diagnostic and prog-
nostic significance [21,22].
Recently several groups have utilised a range of techniques
most notably northern blot analysis, cloning and oligonu-
cleotide microarrays, in order to analyse miRNA expres-
sion profiles in different cancer types [23-26]. In this
study a novel stem-looped TaqMan® RT-PCR method was
used to measure the expression levels of a panel of 160
mature miRNAs in thyroid cell lines containing BRAF
mutation.
Results
Differential miRNA expression using TaqMan™ 
microRNA assays
Stem-looped TaqMan® RT-PCR was used to measure the
expression levels of 160 miRNAs in a collection of cell
lines including a normal thyroid cell lines N-thy-ori 3-1
and two cell lines containing V600E BRAF point mutation
[Nthy-oriBRAF and KAT-10]. A comparison was then
made between Nthy-ori and BRAF mutated cell lines to
determine miRNAs whose expression was differentially
expressed between the two groups. ∆∆CT method was used
to calculate fold change of miRNA expression between
groups. 15 miRNAs were found to be upregulated with a
fold change of > 2 in BRAF mutated cell lines when com-
pared to normal.
Three of these upregulated miRNAs showed significantly
higher fold change than the other upregulated miRNAs,
these are mir-200a, mir-200b and mir-141.
23 miRNAs showed underexpression of > 2 fold when
compared to the normal thyroid cell line. Moreover, three
miRNAs showed significantly more underexpression
compared to the other downregulated miRNAs. These
miRNAs are as follows mir-127, mir-130a and mir-144.
(Table 1 and Figures 1 and 2).
mRNA (transcription) and miRNA (regulation) expression 
correlation
miRNAs interact and regulate their target genes by cleav-
age or translational inhibition [12]. A current challenge is
to identify biologically relevant targets that are regulated
by individual miRNAs. This task is further complicated by
the fact that each miRNA can potentially bind and regu-
late many mRNA targets and each mRNA can be bound
and regulated by several miRNAs. Several publicly availa-
ble databases exist for prediction of miRNA targets. MiR-
Base, PICTAR and TARGETSCAN were used in this study
[26-28].
These three databases were utilized to yield lists of puta-
tive targets for each miRNA which are illustrated in table
Table 1: Differentially expressed miRNAs in BRAF mutated cell 
lines V normal
Upregulated Downregulated
has-mir-128a hsa-mir-122a
has-mir-128b hsa-mir-127
has-mir-135a hsa-mir-130a
has-mir-141 hsa-mir-137
has-mir-150 hsa-mir-138
has-mir-185 hsa-mir-144
has-mir-200a hsa-mir-155
has-mir-200b hsa-mir-181b
has-mir-200c hsa-mir-187
has-mir-203 hsa-mir-190
has-mir-213 hsa-mir-193
has-mir-215 hsa-mir-197
has-mir-330 hsa-mir-222
has-mir-338 hsa-mir-302b
has-mir-34a hsa-mir-302c
hsa-mir-323
hsa-mir-335
hsa-mir-339
hsa-mir-342
hsa-mir-34c
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2. From these lists there are several genes that are biologi-
cally relevant in the context of PTC. The miRNAs which
showed the highest increase in fold change are predicted
to bind genes involved in thyroid function, MAPKKK cas-
cade, retinoic acid receptors, cell adhesion and cell struc-
ture associated genes and genes involved in cell signalling.
miRNAs which showed the largest decrease in fold change
are predicted to regulate and target genes involved in G-
protein mediated signalling, oncogenesis and cell cycle
control. One might predict that a miRNA which is overex-
pressed would be associated with downstream underex-
pression of its target. This regulation can occur either at
the transcript level or the protein level.
Discussion
microRNAs (miRNAs) are now recognized as an addi-
tional layer of post-transcriptional control that must be
considered in order to understand the complexity of gene
expression in humans. miRNAs are now known as a novel
class of gene regulators that are involved in cancer related
processes and deregulation or aberrant expression of miR-
NAs may contribute to human diseases, including cancer.
Calin et al showed down-regulation of miRNA-15 and
miRNA-16 in a majority of chronic lymphatic leukaemia
(CLL). Altered miRNA expression has also been reported
in breast cancer, glioblastoma, lung cancer and colorectal
cancer [29-35].
This study utilized a novel stem-looped TaqMan RT-PCR
method to measure the expression levels of 160 mature
miRNAs in a collection of thyroid cell lines. This method
offers several distinct advantages over conventional
miRNA detection methods including a higher sensitivity
and specificity and a fast and simple methodology. The
aim of this study was to correlate BRAF mutant status with
an associated miRNA profile, with a view to elaborating
the downstream regulatory effect of BRAF mutation.
The data showed a set of differentially expressed miRNAs
in cell lines with BRAF V600E mutation compared to a
Differentially expressed miRNAs Between BRAF V600E harbouring Cell Lines and Normal Thyroid Cell line Figure 1
Differentially expressed miRNAs Between BRAF V600E harbouring Cell Lines and Normal Thyroid Cell line. 
Delta delta CT was performed using Nthy-ori 3-1 as a normal control. The log of the RQ values was used to plot the relative 
fold change of Nthy-BRAF and KAT10 against Nthy-ori 3-1. miRNAs are on the × axis
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Heat map of MiRNA expression Figure 2
Heat map of MiRNA expression. miRNA expression. Each miRNA listed was detected as significantly differentially 
expressed between BRAF mutated cell lines and N-thy-ori. The delta CT values for each miRNA were used to create the heat 
map
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normal thyroid cell line (Table 1). There were 15 overex-
pressed miRNAs and 23 underexpressed miRNAs in these
cell lines compared to the normal cell line. Of these miR-
NAs listed in table 1 only a few have been previously asso-
ciated with other cancers. One of which is miR-127, that
showed down-regulation in BRAF V600E mutated cell
lines. Human miR-127 is embedded in a CpG island and
is silenced in several human cancers including bladder,
prostate and colon cancer and has been suggested to play
a role as a possible tumour suppressor gene [33]. miR-127
also an example of the potential utility of miRNA targeted
therapy in cancer. Saito et al demonstrated that induction
of miR-127 by with 5-aza-20-deoxycytidine and 4-phenyl-
butyric acid, which inhibits DNA methylation and his-
tone deacetylase respectively, reduces expression of the
oncogene BCL6 in bladder cancers [33]. Its utility as a
potential cancer target has yet to be explored in other can-
cers however this suggests the possibility of direct target-
ing of miRNAs that are amplified or upregulated in
patient tumours. Two other miRNAs listed in table 2 have
also been described in other cancers. These include miR-
200b and miR-141 which have been shown to be highly
overexpressed in malignant cholangiocytes and in colon
carcinoma. [18]. This suggests the possibility of miR-200b
and miR-141 down-regulating possible tumour suppres-
sor genes. Of particular interest in this study is the down-
regulation of miR-323 and miR-302b in BRAF mutated
cell line. miRBASE target database predicted that the BRAF
transcript has binding sites for miR-323 and miR-302b to
potentially bind and down- regulate BRAF expression.
A number of miRNAs exhibited a difference in expression
level between KAT10 cell line and normal but did not
show a significant change in the BRAF transfected cell
lines and normal. miRNAs specific to the PTC cell line
with native mutant BRAF included, mir-10a [overex-
pressed with a fold change of 95 in KAT10] mir-23b
[downregulated with a fold change of 2949] and mir-154
[downregulated with a fold change of 142]. It is possible
these miRNAs may play a role in a later stage in tumour
formation and progression; given the transfected cell line
had only been exposed to mutant BRAF for a short period
(3 passages) unlike KAT10 which represents a genuine
PTC which has evolved with BRAT mutant as an intrinsic
component. Alternatively, the difference may reflect the
accumulation of several genetic insults in the process of
tumourigenesis.
Recent studies in miRNA deregulation PTC found an aber-
rant miRNA expression profile in PTCs compared to nor-
mal thyroid tissues [36,37]. In particular, a significant
increase in mir-222, mir-221, mir-146. Our study did not
find any of these miRNAs to be significantly overex-
pressed in the cell lines examined. miR-222 was actually
found to be downregulated in the BRAF mutated cell
lines. Another miRNA these two groups found to be
upregulated albeit less significantly was miR-213, our
study also found miR-213 to be upregulated in BRAF
mutated cell lines [25 fold]. These differences may be due
to the different experimental approaches; Huiling et al
and Pallante et al used miRNA microarrays. They also
used different chemistry and fresh tissue samples; also the
RET and BRAF status of each PTC case was not disclosed.
Prediction of miRNA targets is an immediate challenge in
miRNA research. Several computational approaches have
been implemented for miRNA gene prediction using
methods based on sequence conservation and/or struc-
tural similarity. To overcome the limitations of target pre-
diction three of these databases MiRBase, TARGETSCAN
and PICTAR were used in this study to predict possible tar-
gets of the differentially expressed miRNAs associated
with BRAF mutated (Table 2). Examples of other pro-
grams developed for target identification include RNAhy-
brid, RNA calibrate and RNAeffective. Only a few target
mRNAs have been experimentally proven and studied in
vitro and not all the prediction algorithms yield overlap-
ping lists therefore the lists may contain several false pos-
itives that may fit the criteria but do not interact with the
miRNA in vitro. To overcome this, results were intersected
from these databases to identify the genes commonly pre-
dicted by at least two of the algorithms. The results of the
Table 2: Predicted targets for differentially expressed miRNAs
miR-200a IRS2, MAP3KA, MYH10, SLC20A1, YWHAG, E2F3, RAB38, PPP2R2A, CALCR, MTSS1, RAB30, STXBP1, THRAP2, STRN, 
MATR3, MTPN, FGFR2
miR-128b PLK2, PRKD1, ADORA2B, ZNF385, CASC3, PAIP2, ITGB4BP CRKL, CDH24, ING5, BAG2, EGFR, ST14, THRAP1 CORO1CE2F, 
E2F3, PDGFRA, INSR, CITED2, STX16
miR-141 PDCD4, MYH10, WTAP, STAT5A, PERP, TCF8, FUS, MYL4 LBR, SOCS6, ACTA,1MLANA, CDK2, MAGED4, EIF3S9, 
HISTIH2AG KRT10, XPO4, DCTN3
miR-127 RIMS4, TLK2, BCL6, TFF1, VASH1, PCDH21, BAD, TTGB5, ICAM 3, TMEMG, HIST4H4, APOB, LGALS8, CCNK,
miR-34c RAB43, CELSR3, NOTCH1, MET, CALCR, NOTCH2, THRAP2, TPO52, DAAMI, PDGFRA, MAD1A
miR-302c RAB43, CELSR3, NOTCH1, MET, CALCR, NOTCH2, THRAP2, TPO52, DAAMI, PDGFRA, MAD1A
miR-200a, miR-128b, miR-141 = Upregulated miRNA
miR-127, miR-34c, miR-302c = Downregulated miRNAMolecular Cancer 2007, 6:21 http://www.molecular-cancer.com/content/6/1/21
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potential targets of several differentially expressed miR-
NAs are displayed in table 2.
It is reasonable to expect that targets of downregulated
miRNAs include oncogenes or genes encoding proteins
with potential oncogenic function. Indeed among puta-
tive targets, several genes with potential oncogenic func-
tions were found include RAB35, ERBB4, MAP3K3,
VASP6, KIT, FOSB, NOTCH1. Upregulated miRNAs are
purported to interact with tumour suppressor genes.
Those identified from this study include MAD 4 and ST6.
Several extracellular membrane molecules were also iden-
tified including; myotubulin, MAD1A, Cadherins. In gen-
eral overexpression of an miRNA would be associated
with downregulation of its target miRNA.
Interestingly among these potential gene targets are a
number of genes that have implications in thyroid carci-
noma progression such as genes involved in thyroid func-
tion, cell cycle control, cell signalling, MAPKKK cascade,
retinoic acid receptors, cell adhesion and cell structure
associated genes. Therefore, it seems plausible that this
subset of miRNAs may be important in the progression of
thyroid carcinoma by working together or independently
to regulate genes involved in thyroid tumourigenesis
Our group has also previously examined gene expression
levels in these same cell lines. This analysis was done by
evaluating genome-wide gene expression levels in BRAF
mutated cell lines and matched normal thyroid cell lines
using the Applied Biosystems Gene Expression Arrays.
Treatment comparisons were preformed resulting in lists
of differentially expressed genes (Figure 3). These gene
lists were uploaded into PANTHER (Protein ANalysis
THrough Evolutionary Relationships) classification sys-
tem and the software statistically compared them to a ref-
erence list to look for under and over-represented
molecular functions and biological process. Analysis
revealed a set of genes associated with mutant BRAF
expression which are involved in processes such as apop-
tosis, chromosomal instability, invasiveness and metasta-
sis and proliferation. Other genes identified were shown
to be involved in the insulin-like growth factor pathway
(including (insulin-like growth factor binding protein)
IGFBP4, (insulin receptor substrate) IRSI, GRB14, PLAG1
and IGF2) and the Wnt signaling pathway suggesting their
importance in BRAF signalling.
Up and down regulation of cell adhesion and chromo-
some remodelling molecules were also shown. BRAF
mutation has previously been shown to induce chromo-
some instability and decrease cell- cell interactions [38]
and our data further corroborates the involvement of
these processes in papillary thyroid carcinoma. Not sur-
prisingly genes involved in the MAPK pathway, of which
BRAF is an integral part, showed an increase in expression.
Hierarchical Clustering of BRAF mutated Cell lines Figure 3
Hierarchical Clustering of BRAF mutated Cell lines. In (a) The column dendrogram clearly shows cases clustering on 
the basis of BRAF mutation. To the left are the normal thyroid cell lines with no BRAF mutation and to the right are Nthy-
BRAF with V600E mutation. In (b) The denodrogran shows cases again clustering on the basis of BRAF mutation. To the left 
are the PTCs with BRAF V600E mutation and to the right are the normal thyroid cell lines with no mutation.Molecular Cancer 2007, 6:21 http://www.molecular-cancer.com/content/6/1/21
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Among these genes were DDIT, DUSP6, TFPI-2, Seladin-1,
MAP3K12, and GRB14. These results provided an insight
into the different pathways through which BRAF exerts its
oncogenic effect and emphasised the importance of the
MAPK and Wnt signalling pathways in thyroid tumour
formation.
The list of putative miRNA targets (as defined above in
table table 1) correlated with the list of differentially
expressed genes on analysis. This is illustrated in table 3.
It is interesting to speculate that these genes are regulated
by their corresponding miRNA thereby contributing to
tumour development in thyroid. These observations
should be placed in context, in so far as predictive data-
bases are incomplete and target selection is essentially
speculative and involves a degree of subjectivity as these
target mRNAs have not been experimentally proven and
studied in vitro.
In summary this study revealed a set of miRNAs associated
with expression of mutant BRAFV600E oncogene in PTC cell
lines when compared to a normal thyroid cell line. The
BRAF oncogene may influence miRNA expression directly
or indirectly by altering the expression patterns of genes,
such as transcription factors, involved in tumour progres-
sion or indeed the genes involved in the biogenesis and
synthesis of miRNAs such as those from the RISC complex
and miRNA machinery. These miRNAs associated with
BRAF oncogene as listed in Table 1 may contribute to
tumour formation by regulating genes involved in the
MAPK pathway in which BRAF plays a role.
This data suggests the potential utility of miRNA expres-
sion patterns as a molecular screen for PTC to use as a
diagnostic adjuvant to already established morphological
criteria. A recent study by this group examined the effect
the ret/PTC 1 oncogene has on miRNA expression in PTC
cell lines. ret/PTC 1 rearrangements are generally associ-
ated with classic papillary architecture and indolent
behaviour in thyroid carcinoma. This study showed a dis-
tinct pattern of miRNAs associated with the ret/PTC 1
oncogene when compared to a normal thyroid cell lines
[39].
It is noteworthy that different miRNA expression profiles
have been shown contingent upon ret/PTC 1 activated
and BRAF mutated cell lines. This suggests that miRNA
expression analysis may also be of prognostic significance.
Further miRNA analysis in a larger cohort of samples will
help validate and consolidate the results discussed above.
Table 4 illustrates a compilation of miRNAs that are differ-
entially expressed in PTC cell lines (either ret/PTC-1 or
BRAF mutant), suggesting an important role for these
miRNAs in thyroid neoplasia progression independent of
Table 3: miRNAs and Predicted Targets.
Up-regulated Genes Potential Binding Partner (down-regulated)
PGM5 miR-137
DUSP6 miR-138
TLE miR-323
HSPH1 miR-181b
PCGF1 miR-138
CDK2AP2 miR-302c, miR-302b
DDIT3 miR-144
SLC14A1 miR-222
MANEA miR-302b, miR-302c
ELP4 miR-122a
APIP miR-181b
PEX7 miR-190
Down-regulated Genes Potential Binding Partner (up-regulated)
SYTL2 miR-128a, miR-128b
GJB3 miR-34a
SDC4 miR-141, miR-215
CREBL2 miR-141, miR-200a,
CCL2 miR-141, miR-200a
GYG2 miR-215
HIATL1 miR-34a
ZMYND11 miR-200a
ADAMTS4 miR-141
Differentially expressed miRNAs in BRAF mutated cell lines. Red = Upregulated. Green = DownregulatedMolecular Cancer 2007, 6:21 http://www.molecular-cancer.com/content/6/1/21
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molecular trigger. They may be involved in regulating the
central MAPK pathway involved in thyroid tumourigene-
sis in which RET and BRAF oncogenes play a part.
Conclusion
Although the exact function of many miRNAs remains to
be elucidated it is clear that miRNAs potentially have a
broad influence over several diverse genetic pathways and
that their deregulation is likely to contribute to disease
including cancer. An exciting future prospect is that the
miRNA patterns associated with a particular tumour may
ultimately be of diagnostic and prognostic significance
and contribute to the understanding of the molecular
pathogenesis and gene regulatory processes of cancer.
Materials and methods
Cell culture and transfection
Nthy-ori 3-1 (ECACC, Wiltshire, UK) is a thyroid follicu-
lar epithelial cell line derived from normal thyroid tissue
of an adult that has been transfected with a plasmid
encoding for the SV40 large T gene. KAT10 is derived from
a papillary thyroid carcinoma cell line with heterozygous
BRAF V600E mutation. Both cell lines were grown to con-
fluence in a humidified atmosphere containing 5% CO2 at
37°C in the following plating medium: RPMI 1640 with
2 mM L-glutamine, 10% Foetal calf serum (FCS), Penicil-
lin (100 U/ml) and Streptomycin (100 µg/ml). A BRAF
V600E expressing plasmid, pMCEF-V600EB-RAF, was
transfected into Nthy-ori 3-1. Transfections were carried
out using Genejuice™ transfection agent (Novagen, Ger-
many) using the recommended protocol and transfected
cells were grown in the presence of Gentamicin (Sigma
Aldrich) antibiotic to yield pure cultures.
Nucleic acid extraction
Following trypsinisation of cultured cells, cell pellets (3–
4 × 106 cells) were collected and total RNA was extracted
using RNeasy® mini kit (Qiagen Ltd., West Sussex, UK).
RNA quantity and quality are assessed using a NanoDrop®
ND-1000 Spectrophotometer (Wilmington, USA) and
RNA 6000 Nano LabChip® Kit in conjunction with the
Agilent 2100 Bioanalyser (Agilent technologies, Wald-
bronn, Germany) as illustrated in figure 4. Taqman® SNP
detection was used for BRAF V600E mutation detection as
previously described by Smyth et al [40]. Primers and
probes used in this experiment were designed and used to
the manufacturer's recommendations. The primers/
probes used were as follows: 5' CAT GAA GAC CTC ACA
GTA AAA ATA GGT GAT 3' [BRAF-F], 5' GGA TCC AGA
CAA CTG TTC AAA CTG A 3' [BRAF-R], VIC-5' CCA TCG
AGA TTT CAC TGT AG 3' [BRAF-PWT], and FAM-5' CCA
TCG AGA TTT CTC TGT AG 3' [BRAF-PMUT]. Amplification
and analysis was performed using an ABI Prism 7000
Sequence Detection System (Applied Biosystems, CA,
USA) for 40 cycles (92°C for 15 sec, 60°C for 1 min).
Western blot analysis was carried out on the transfected
cell lines to confirm BRAF protein expression.
Bioanalyser "virtual" gel electrophoresis for N-thy-ori Cell  Lines Figure 4
Bioanalyser "virtual" gel electrophoresis for N-thy-
ori Cell Lines. Lane 1: Nthy-ori rep1; Lane 2:Nthy-ori rep 
2; Lane 3: Nthyori rep3
Table 4: Differentially Expressed miRNA in ret/PTC 1 and BRAF 
mutated cell lines
Upregulated miRNAs Downregulated miRNAs
miR-128a miR-127
miR-128b miR-302b
miR-185 miR-302c
miR-200a miR-323
miR-200b miR-370
miR-213Molecular Cancer 2007, 6:21 http://www.molecular-cancer.com/content/6/1/21
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Microarray analysis
The Applied Biosystems 1700 Expression Array System is
based on a microarray design that represents the whole
human genome. The V.2 array has 32,878 60-mer oligo-
nucleotide probes for the interrogation of 29,098 individ-
ual human gene and more than 1,000 control probes. V2
arrays were used to analyse the transcriptional profiles of
the cell line RNA samples in this study. Digoxigenin-UTP
labeled cRNA was generated and linearly amplified from
2 µg of total RNA using Applied Biosystems Chemilumi-
nescent RT-IVT Labelling Kit v 2.0 following the manufac-
turer's protocol. Array hybridization, chemiluminescence
detection, image acquisition and analysis were performed
using Applied Biosystems Chemiluminescence Detection
Kit and 1700 Chemiluminescent Mircoarray Analyzer fol-
lowing manufacturer's guidelines. Each microarray was
initially pre-hybridised at 55°C for 1 hr in hybridization
buffer with blocking reagent. 10 µg of labeled cRNA tar-
gets were fragemented by incubating with fragmentation
buffer at 60°C for 30 min, mixed with internal control tar-
get (ICT, 24-mer oligo labeled with LIZ fluorescent dye)
and hybridized to each pre-hybed microarray in a 1.5 ml
volume at 55°C for 16 hr. After hybridization, the arrays
were washed with hybridization wash buffer and chemi-
luminscence rinse buffer. Enhanced chemiluminescenct
signals were generated by incubating arrays with anti-dig-
oxigenin alkaline phosphatase, enhanced with Chemilu-
minescence Enhancing Solution and finally by adding
Chemiluminescence Substrate. Images were collected for
each microarray using the 1700 analyser. Images were
autogridded and the chemiluminescent signals were
quantified, corrected for background and spot and spa-
tially normalized. Replicates were performed. Microarrays
were analysed using Spotfire Decision Site™ for functional
genomics (Spotfire AB, Göteborg, Sweden) and R version
1.9.1 [a free language and environment for statistical anal-
ysis and graphics] (R Development Core Team, 2004).
miRNA analysis
Applied Biosystems TaqMan® microRNA (miRNA) assays
are designed to detect and quantify mature miRNAs using
a looped-primer real time PCR. The human early access
panel used in this study contained 160 individual assays
for identified human miRNAs. The assay involved 2 steps:
Step one; a Stem-looped RT, and Step two; a Real Time
PCR. Briefly, single stranded cDNA was generated from
total RNA sample by reverse transcription using the
Applied Biosystems High-Capacity cDNA Archive Kit
(Applied Biosystems, CA, USA) following manufacturer's
protocol. RT reactions contained 10 ng of total RNA, 50
nM stem-looped RT primer, 1 × RT buffer, 0.25 mM each
of dNTPs, 3.33 U/µl Multiscribe reverse transcriptase and
0.25 U/µl RNase Inhibitor. PCR amplification was carried
out using sequence specific primers on the Applied Bio-
systems 7900 HT Fast Real-Time PCR system. The reac-
tions were incubated in a 96-well optical plate at 95°C for
10 min, following by 40 cycles of 95°C for 15 s and 60°C
for 10 min. Analysis of relative miRNA expression data
was performed using ∆∆CT method with hsa-let-7a as an
endogenous control [41]. Two negative controls were also
used, ath-mir159a and cel-lin-4 as they show no expres-
sion in human tissue.
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